Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Primary Biliary Cirrhosis
NCT02078882Phase 4Completed
- Start
- Sep 2014
- Primary completion
- Oct 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abatacept in primary biliary cholangitis (PBC). Primary endpoint: Biochemical Response at 24 weeks. Started Sep 2014; status: completed.
02
Drugs
abatacept
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02078882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078882.